当院における仙骨脊索腫に対する陽子線治療の後方視的検討　　　　　　　　　　　　　　　
檜垣 朔, 田口 大志, 宮崎 智彦, 森 崇, 西岡 健太郎, 加藤 徳雄, 橋本 孝之, 田村 昌也, 高尾 聖心, 松浦 妙子, 青山 英史
日本医学放射線学会秋季臨床大会抄録集, 60回, S442, S442, (公社)日本医学放射線学会, Sep. 2024
Japanese

A Single-Institution Prospective Study To Evaluate the Safety and Efficacy of Real- Time Image-Gated Spot-Scanning Proton Therapy (RGPT) for Prostate Cancer.
Kentaro Nishioka, Takayuki Hashimoto, Takashi Mori, Yusuke Uchinami, Rumiko Kinoshita, Norio Katoh, Hiroshi Taguchi, Koichi Yasuda, Yoichi M Ito, Seishin Takao, Masaya Tamura, Taeko Matsuura, Shinichi Shimizu, Hiroki Shirato, Hidefumi Aoyama
Advances in radiation oncology, 9, 5, 101464, 101464, May 2024, [Peer-reviewed], [International Magazine]
English, Scientific journal, PURPOSE: In real-time image-gated spot-scanning proton therapy (RGPT), the dose distribution is distorted by gold fiducial markers placed in the prostate. Distortion can be suppressed by using small markers and more than 2 fields, but additional fields may increase the dose to organs at risk. Therefore, we conducted a prospective study to evaluate the safety and short-term clinical outcome of RGPT for prostate cancer. METHODS AND MATERIALS: Based on the previously reported frequency of early adverse events (AE) and the noninferiority margin of 10%, the required number of cases was calculated to be 43 using the one-sample binomial test by the Southwest Oncology Group statistical tools with the one-sided significance level of 2.5% and the power 80%. Patients with localized prostate cancer were enrolled and 3 to 4 pure gold fiducial markers of 1.5-mm diameter were inserted in the prostate. The prescribed dose was 70 Gy(relative biologic effectiveness) in 30 fractions, and treatment was performed with 3 fields from the left, right, and the back, or 4 fields from either side of slightly anterior and posterior oblique fields. The primary endpoint was the frequency of early AE (≥grade 2) and the secondary endpoint was the biochemical relapse-free survival rate and the frequency of late AE. RESULTS: Forty-five cases were enrolled between 2015 and 2017, and all patients completed the treatment protocol. The median follow-up period was 63.0 months. The frequency of early AE (≥grade 2) was observed in 4 cases (8.9%), therefore the noninferiority was verified. The overall 5-year biochemical relapse-free survival rate was 88.9%. As late AE, grade 2 rectal bleeding was observed in 8 cases (17.8%). CONCLUSIONS: The RGPT for prostate cancer with 1.5-mm markers and 3- or 4- fields was as safe as conventional proton therapy in early AE, and its efficacy was comparable with previous studies.

A new predictive parameter for dose‐volume metrics in intensity‐modulated radiation therapy planning for prostate cancer: Initial phantom study
Yuki Saito, Ryusuke Suzuki, Naoki Miyamoto, Kenneth Lee Sutherland, Takahiro Kanehira, Masaya Tamura, Takashi Mori, Kentaro Nishioka, Takayuki Hashimoto, Hidefumi Aoyama
Journal of Applied Clinical Medical Physics, Apr. 2024, [Peer-reviewed]
Scientific journal

肝細胞癌陽子線治療効果予測におけるADC値指標の検討　　　　　　　　　　　　　　　
藤田 祥博, 加藤 徳雄, 打浪 雄介, 田口 大志, 西岡 健太郎, 森 崇, 安田 耕一, 小泉 富基, 大塚 愛美, 高尾 聖心, 田村 昌也, Sutherland Kenneth, Khin Khin Tha, 伊藤 陽一, 青山 英史
Japanese Journal of Radiology, 41, Suppl., 10, 10, (公社)日本医学放射線学会, Feb. 2023
Japanese

Hyperfractionated intensity-modulated proton therapy for pharyngeal cancer with variable relative biological effectiveness: A simulation study.
Koki Kasamatsu, Taeko Matsuura, Koichi Yasuda, Koichi Miyazaki, Seishin Takao, Masaya Tamura, Manami Otsuka, Yusuke Uchinami, Hidefumi Aoyama
Medical physics, 49, 12, 7815, 7825, 27 Oct. 2022, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: The relative biological effectiveness (RBE) of proton is considered to be dependent on biological parameters and fractional dose. While hyperfractionated photon therapy was effective in the treatment of patients with head and neck cancers, its effect in intensity-modulated proton therapy (IMPT) under the variable RBE has not been investigated in detail. PURPOSE: To study the effect of variable RBE on hyperfractionated IMPT for the treatment of pharyngeal cancer. We investigated the biologically effective dose (BED) to determine the theoretical effective hyperfractionated schedule. METHODS: The treatment plans of three pharyngeal cancer patients were used to define the ΔBED for the clinical target volume (CTV) and soft tissue (acute and late reaction) as the difference between the BED for the altered schedule with variable RBE and conventional schedule with constant RBE. The ΔBED with several combinations of parameters (treatment days, number of fractions, and prescribed dose) was comprehensively calculated. Of the candidate schedules, the one that commonly gave a higher ΔBED for CTV was selected as the resultant schedule. The BED volume histogram was used to compare the influence of variable RBE and fractionation. RESULTS: In the conventional schedule, compared with the constant RBE, the variable RBE resulted in a mean 2.6 and 2.7 Gy reduction of BEDmean for the CTV and soft tissue (acute reaction) of the three plans, respectively. Moreover, the BEDmean for soft tissue (late reaction) increased by 7.4 Gy, indicating a potential risk of increased RBE. Comprehensive calculation of the ΔBED resulted in the hyperfractionated schedule of 80.52 Gy (RBE = 1.1)/66 fractions in 6.5 weeks. When variable RBE was used, compared with the conventional schedule, the hyperfractionated schedule increased the BEDmean for CTV by 7.6 Gy; however, this was associated with a 7.8 Gy increase for soft tissue (acute reaction). The BEDmean for soft tissue (late reaction) decreased by 2.4 Gy. CONCLUSION: The results indicated a potential effect of the variable RBE on IMPT for pharyngeal cancer but with the possibility that hyperfractionation could outweigh this effect. Although biological uncertainties require conservative use of the resultant schedule, hyperfractionation is expected to be an effective strategy in IMPT for pharyngeal cancer.

A study on predicting cases that would benefit from proton beam therapy in primary liver tumors of less than or equal to 5 cm based on the estimated incidence of hepatic toxicity
Yusuke Uchinami, Norio Katoh, Ryusuke Suzuki, Takahiro Kanehira, Masaya Tamura, Seishin Takao, Taeko Matsuura, Naoki Miyamoto, Yoshihiro Fujita, Fuki Koizumi, Hiroshi Taguchi, Koichi Yasuda, Kentaro Nishioka, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama
Clinical and Translational Radiation Oncology, 35, 70, 75, Elsevier BV, Jul. 2022, [Peer-reviewed]
Scientific journal

A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer
Takaaki Yoshimura, Kentaro Nishioka, Takayuki Hashimoto, Kazuya Seki, Shouki Kogame, Sodai Tanaka, Takahiro Kanehira, Masaya Tamura, Seishin Takao, Taeko Matsuura, Keiji Kobashi, Fumi Kato, Hidefumi Aoyama, Shinichi Shimizu
Physics and Imaging in Radiation Oncology, 20, 23, 29, Elsevier BV, Oct. 2021, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND AND PURPOSE: Urethra-sparing radiation therapy for localized prostate cancer can reduce the risk of radiation-induced genitourinary toxicity by intentionally underdosing the periurethral transitional zone. We aimed to compare the clinical impact of a urethra-sparing intensity-modulated proton therapy (US-IMPT) plan with that of conventional clinical plans without urethral dose reduction. MATERIALS AND METHODS: This study included 13 patients who had undergone proton beam therapy. The prescribed dose was 63 GyE in 21 fractions for 99% of the clinical target volume. To compare the clinical impact of the US-IMPT plan with that of the conventional clinical plan, tumor control probability (TCP) and normal tissue complication probability (NTCP) were calculated with a generalized equivalent uniform dose-based Lyman-Kutcher model using dose volume histograms. The endpoints of these model parameters for the rectum, bladder, and urethra were fistula, contraction, and urethral stricture, respectively. RESULTS: The mean NTCP value for the urethra in US-IMPT was significantly lower than that in the conventional clinical plan (0.6% vs. 1.2%, p < 0.05). There were no statistically significant differences between the conventional and US-IMPT plans regarding the mean minimum dose for the urethra with a 3-mm margin, TCP value, and NTCP value for the rectum and bladder. Additionally, the target dose coverage of all plans in the robustness analysis was within the clinically acceptable range. CONCLUSIONS: Compared with the conventional clinically applied plans, US-IMPT plans have potential clinical advantages and may reduce the risk of genitourinary toxicities, while maintaining the same TCP and NTCP in the rectum and bladder.

Assessment of the confidence interval in the multivariable normal tissue complication probability model for predicting radiation-induced liver disease in primary liver cancer.
Anussara Prayongrat, Natchalee Srimaneekarn, Sira Sriswasdi, Yoichi M Ito, Norio Katoh, Masaya Tamura, Yasuhiro Dekura, Chie Toramatsu, Chonlakiet Khorprasert, Napapat Amornwichet, Petch Alisanant, Yuichi Hirata, Anthony Hayter, Hiroki Shirato, Shinichi Shimizu, Keiji Kobashi
Journal of radiation research, 62, 3, 483, 493, 12 May 2021, [International Magazine]
English, Scientific journal, We developed a confidence interval-(CI) assessing model in multivariable normal tissue complication probability (NTCP) modeling for predicting radiation-induced liver disease (RILD) in primary liver cancer patients using clinical and dosimetric data. Both the mean NTCP and difference in the mean NTCP (ΔNTCP) between two treatment plans of different radiotherapy modalities were further evaluated and their CIs were assessed. Clinical data were retrospectively reviewed in 322 patients with hepatocellular carcinoma (n = 215) and intrahepatic cholangiocarcinoma (n = 107) treated with photon therapy. Dose-volume histograms of normal liver were reduced to mean liver dose (MLD) based on the fraction size-adjusted equivalent uniform dose. The most predictive variables were used to build the model based on multivariable logistic regression analysis with bootstrapping. Internal validation was performed using the cross-validation leave-one-out method. Both the mean NTCP and the mean ΔNTCP with 95% CIs were calculated from computationally generated multivariate random sets of NTCP model parameters using variance-covariance matrix information. RILD occurred in 108/322 patients (33.5%). The NTCP model with three clinical and one dosimetric parameter (tumor type, Child-Pugh class, hepatitis infection status and MLD) was most predictive, with an area under the receiver operative characteristics curve (AUC) of 0.79 (95% CI 0.74-0.84). In eight clinical subgroups based on the three clinical parameters, both the mean NTCP and the mean ΔNTCP with 95% CIs were able to be estimated computationally. The multivariable NTCP model with the assessment of 95% CIs has potential to improve the reliability of the NTCP model-based approach to select the appropriate radiotherapy modality for each patient.

Analysis of acute-phase toxicities of intensity-modulated proton therapy using a model-based approach in pharyngeal cancer patients.
Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Seishin Takao, Masaya Tamura, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Takatsugu Mizumachi, Takashi Mori, Kentaro Nishioka, Motoyasu Shido, Norio Katoh, Hiroshi Taguchi, Noriyuki Fujima, Rikiya Onimaru, Isao Yokota, Keiji Kobashi, Shinichi Shimizu, Akihiro Homma, Hiroki Shirato, Hidefumi Aoyama
Journal of radiation research, 62, 2, 329, 337, 10 Mar. 2021, [Peer-reviewed], [International Magazine]
English, Scientific journal, Pharyngeal cancer patients treated with intensity-modulated proton therapy (IMPT) using a model-based approach were retrospectively reviewed, and acute toxicities were analyzed. From June 2016 to March 2019, 15 pharyngeal (7 naso-, 5 oro- and 3 hypo-pharyngeal) cancer patients received IMPT with robust optimization. Simulation plans for IMPT and intensity-modulated X-ray therapy (IMXT) were generated before treatment. We also reviewed 127 pharyngeal cancer patients with IMXT in the same treatment period. In the simulation planning comparison, all of the normal-tissue complication probability values for dysphagia, dysgeusia, tube-feeding dependence and xerostomia were lower for IMPT than for IMXT in the 15 patients. After completing IMPT, 13 patients completed the evaluation, and 12 of these patients had a complete response. The proportions of patients who experienced grade 2 or worse acute toxicities in the IMPT and IMXT cohorts were 21.4 and 56.5% for dysphagia (P < 0.05), 46.7 and 76.3% for dysgeusia (P < 0.05), 73.3 and 62.8% for xerostomia (P = 0.43), 73.3 and 90.6% for mucositis (P = 0.08) and 66.7 and 76.4% for dermatitis (P = 0.42), respectively. Multivariate analysis revealed that IMPT was independently associated with a lower rate of grade 2 or worse dysphagia and dysgeusia. After propensity score matching, 12 pairs of IMPT and IMXT patients were selected. Dysphagia was also statistically lower in IMPT than in IMXT (P < 0.05). IMPT using a model-based approach may have clinical benefits for acute dysphagia.

Quantitative analysis of treatments using real-time image gated spot-scanning with synchrotron-based proton beam therapy system log data.
Takaaki Yoshimura, Shinichi Shimizu, Takayuki Hashimoto, Kentaro Nishioka, Norio Katoh, Hiroshi Taguchi, Koichi Yasuda, Taeko Matsuura, Seishin Takao, Masaya Tamura, Sodai Tanaka, Yoichi M Ito, Yuto Matsuo, Hiroshi Tamura, Kenji Horita, Kikuo Umegaki, Hiroki Shirato
Journal of applied clinical medical physics, 21, 12, 10, 19, Dec. 2020, [International Magazine]
English, Scientific journal, A synchrotron-based real-time image gated spot-scanning proton beam therapy (RGPT) system with inserted fiducial markers can irradiate a moving tumor with high accuracy. As gated treatments increase the beam delivery time, this study aimed to investigate the frequency of intra-field adjustments corresponding to the baseline shift or drift and the beam delivery efficiency of a synchrotron-based RGPT system. Data from 118 patients corresponding to 127 treatment plans and 2810 sessions between October 2016 and March 2019 were collected. We quantitatively analyzed the proton beam delivery time, the difference between the ideal beam delivery time based on a simulated synchrotron magnetic excitation pattern and the actual treatment beam delivery time, frequency corresponding to the baseline shift or drift, and the gating efficiency of the synchrotron-based RGPT system according to the proton beam delivery machine log data. The mean actual beam delivery time was 7.1 min, and the simulated beam delivery time in an ideal environment with the same treatment plan was 2.9 min. The average difference between the actual and simulated beam delivery time per session was 4.3 min. The average frequency of intra-field adjustments corresponding to baseline shift or drift and beam delivery efficiency were 21.7% and 61.8%, respectively. Based on our clinical experience with a synchrotron-based RGPT system, we determined the frequency corresponding to baseline shift or drift and the beam delivery efficiency using the beam delivery machine log data. To maintain treatment accuracy within ± 2.0 mm, intra-field adjustments corresponding to baseline shift or drift were required in approximately 20% of cases. Further improvements in beam delivery efficiency may be realized by shortening the beam delivery time.

Analysis of treatment process time for real-time-image gated-spot-scanning proton-beam therapy (RGPT) system.
Takaaki Yoshimura, Shinichi Shimizu, Takayuki Hashimoto, Kentaro Nishioka, Norio Katoh, Tetsuya Inoue, Hiroshi Taguchi, Koichi Yasuda, Taeko Matsuura, Seishin Takao, Masaya Tamura, Yoichi M Ito, Yuto Matsuo, Hiroshi Tamura, Kenji Horita, Kikuo Umegaki, Hiroki Shirato
Journal of applied clinical medical physics, 21, 2, 38, 49, Feb. 2020, [Peer-reviewed], [International Magazine]
English, We developed a synchrotron-based real-time-image gated-spot-scanning proton-beam therapy (RGPT) system and utilized it to clinically operate on moving tumors in the liver, pancreas, lung, and prostate. When the spot-scanning technique is linked to gating, the beam delivery time with gating can increase, compared to that without gating. We aim to clarify whether the total treatment process can be performed within approximately 30 min (the general time per session in several proton therapy facilities), even for gated-spot-scanning proton-beam delivery with implanted fiducial markers. Data from 152 patients, corresponding to 201 treatment plans and 3577 sessions executed from October 2016 to June 2018, were included in this study. To estimate the treatment process time, we utilized data from proton beam delivery logs during the treatment for each patient. We retrieved data, such as the disease site, total target volume, field size at the isocenter, and the number of layers and spots for each field, from the treatment plans. We quantitatively analyzed the treatment process, which includes the patient load (or setup), bone matching, marker matching, beam delivery, patient unload, and equipment setup, using the data obtained from the log data. Among all the cases, 90 patients used the RGPT system (liver: n = 34; pancreas: n = 5; lung: n = 4; and prostate: n = 47). The mean and standard deviation (SD) of the total treatment process time for the RGPT system was 30.3 ± 7.4 min, while it was 25.9 ± 7.5 min for those without gating treatment, excluding craniospinal irradiation (CSI; head and neck: n = 16, pediatric: n = 31, others: n = 15); for CSI (n = 11) with two or three isocenters, the process time was 59.9 ± 13.9 min. Our results demonstrate that spot-scanning proton therapy with a gating function can be achieved in approximately 30-min time slots.

Liver phantom design and dosimetric verification in participating institutions for a proton beam therapy in patients with resectable hepatocellular carcinoma: Japan Clinical Oncology Group trial (JCOG1315C)
Teiji Nishio, Hidenobu Tachibana, Yuki Kase, Kenji Hotta, Mitsuhiro Nakamura, Masaya Tamura, Toshiyuki Terunuma, Toshiyuki Toshito, Haruo Yamashita, Satoshi Ishikura, Hiroshi Fuji, Tetsuo Akimoto, Yasumasa Nishimura
Radiotherapy and Oncology, 140, 98, 104, Nov. 2019, [Peer-reviewed]
Scientific journal

Initial Clinical Outcomes of Real-Time-Image Gated Spot-Scanning Proton Beam Therapy for Hepatocellular Carcinomas
N. Katoh, Y. Uchinami, D. Abo, S. Takao, T. Inoue, H. Taguchi, R. Morita, T. Soyama, T. Hashimoto, R. Onimaru, A. Prayongrat, M. Tamura, T. Matsuura, S. Shimizu, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 105, 1, E222, E223, Elsevier BV, Sep. 2019, [Peer-reviewed]
Scientific journal

局所進行食道癌に対してspot scanning法による根治的化学陽子線療法を施行した一例　　　　　　　　　　　　　　　
宮崎 智彦, 打浪 雄介, 田口 大志, 加藤 徳雄, 清水 伸一, 白土 博樹, 中積 宏之, 中野 真太郎, 坂本 直哉, 高尾 聖心, 田村 昌也, 松浦 妙子
日本医学放射線学会秋季臨床大会抄録集, 55回, S520, S520, (公社)日本医学放射線学会, Sep. 2019
Japanese

The Potential Benefit of Adaptive Intensity Modulated Proton Therapy in Nasopharyngeal Carcinoma: Planning Comparison Study
H. Minatogawa, K. Yasuda, T. Matsuura, R. Onimaru, T. Yoshimura, S. Takao, Y. Matsuo, Y. Dekura, R. Suzuki, M. Tamura, N. Miyamoto, S. Shimizu, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 105, 1, E394, E394, Elsevier BV, Sep. 2019
Scientific journal

Clinical experience of craniospinal intensity-modulated spot-scanning proton therapy using large fields for central nervous system medulloblastomas and germ cell tumors in children, adolescents, and young adults.
Takayuki Hashimoto, Shinichi Shimizu, Seishin Takao, Shunsuke Terasaka, Akihiro Iguchi, Hiroyuki Kobayashi, Takashi Mori, Takaaki Yoshimura, Yuto Matsuo, Masaya Tamura, Taeko Matsuura, Yoichi M Ito, Rikiya Onimaru, Hiroki Shirato
Journal of radiation research, 60, 4, 527, 537, 01 Jul. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, The outcomes of intensity-modulated proton craniospinal irradiation (ipCSI) are unclear. We evaluated the clinical benefit of our newly developed ipCSI system that incorporates two gantry-mounted orthogonal online X-ray imagers with a robotic six-degrees-of-freedom patient table. Nine patients (7-19 years old) were treated with ipCSI. The prescribed dose for CSI ranged from 23.4 to 36.0 Gy (relative biological effectiveness) in 13-20 fractions. Four adolescent and young adult (AYA) patients (15 years or older) were treated with vertebral-body-sparing ipCSI (VBSipCSI). Myelosuppression following VBSipCSI was compared with that of eight AYA patients treated with photon CSI at the same institution previously. The mean homogeneity index (HI) in the nine patients was 0.056 (95% confidence interval: 0.044-0.068). The mean time from the start to the end of all beam delivery was 37 min 39 s ± 2 min 24 s (minimum to maximum: 22 min 49 s - 42 min 51 s). The nadir white blood cell, hemoglobin, and platelet levels during the 4 weeks following the end of the CSI were significantly higher in the VBSipCSI group than in the photon CSI group (P = 0.0071, 0.0453, 0.0024, respectively). The levels at 4 weeks after the end of CSI were significantly higher in the VBSipCSI group than in the photon CSI group (P = 0.0023, 0.0414, 0.0061). Image-guided ipCSI was deliverable in a reasonable time with sufficient HI. Using VBSipCSI, AYA patients experienced a lower incidence of serious acute hematological toxicity than AYA patients treated with photon CSI.

The normal tissue complication probability model-based approach considering uncertainties for the selective use of radiation modality in primary liver cancer patients.
Anussara Prayongrat, Keiji Kobashi, Yoichi M Ito, Norio Katoh, Masaya Tamura, Yasuhiro Dekura, Chie Toramatsu, Chonlakiet Khorprasert, Napapat Amornwichet, Petch Alisanant, Hiroki Shirato, Shinichi Shimizu
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 135, 100, 106, Jun. 2019, [International Magazine]
English, Scientific journal, PURPOSE: To predict the probability of radiation-induced liver toxicity (RILT) and implement the normal tissue complication probability (NTCP) model-based approach considering confidence intervals (CIs) to select patients for new treatment techniques, such as proton beam therapy, based on a certain NTCP reduction (ΔNTCP) threshold for primary liver cancer patients. METHODS AND MATERIALS: Common Toxicity Criteria for Adverse Events (CTCAE) grade ≥2 RILT was scored. The Lyman NTCP models predicting the probability of CTCAE grade ≥2 RILT as a function of the fraction-size adjusted mean liver dose (MLD), using reference fraction size = 2 Gy/fraction and α/β ratio = 2 Gy, were fitted using the maximum likelihood method. At certain combinations of MLDs, ΔNTCP with a CI was evaluated by the delta method. RESULTS: Of the 239 patients, the incidence of CTCAE grade ≥2 RILT was 55% (46% in the Child-Pugh (CP)-A vs. 81% in the CP-B/C, p < 0.001). Among 180 CP-A patients, 40% who had viral hepatitis infections experienced toxicity vs. 32% in the nonhepatitis subgroup. The MLD was 18 Gy in the toxicity group vs. 16.1 Gy in the nontoxicity group (p = 0.002). The estimated NTCP model parameters specific to the patient subgroups and the ΔNTCP with CI assuming a particular CP classification and viral hepatitis infection status were considerably different which possible changed treatment decision. CONCLUSIONS: Patients with CP-A and viral hepatitis infection or CP-B/C cirrhosis had greater susceptibility to CTCAE grade ≥2 RILT. The estimated NTCP and ΔNTCP for individual patients along with a consideration of uncertainties improve the reliability of the NTCP model-based approach.

同時期に異所性に発生した悪性腫瘍に対して、二部位同時にIMRTを施行した症例　　　　　　　　　　　　　　　
湊川 英樹, 安田 耕一, 白土 博樹, 土屋 和彦, 原田 八重, 水町 貴諭, 坂下 智博, 本間 明宏, 福田 諭, 石嶋 漢, 宮本 直樹, 高尾 聖心, 鈴木 隆介, 松浦 妙子, 牧永 綾乃, 田村 昌也
Japanese Journal of Radiology, 36, Suppl., 6, 6, (公社)日本医学放射線学会, Feb. 2018
Japanese

Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients
Masaya Tamura, Hideyuki Sakurai, Masashi Mizumoto, Satoshi Kamizawa, Shigeyuki Murayama, Haruo Yamashita, Seishin Takao, Ryusuke Suzuki, Hiroki Shirato, Yoichi M. Ito
JOURNAL OF RADIATION RESEARCH, 58, 3, 363, 371, May 2017, [Peer-reviewed]
English, Scientific journal

Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients
Tamura,Masaya, Sakurai,Hideyuki, Mizumoto,Masashi, Kamizawa,Satoshi, Murayama,Shigeyuki, Yamashita,Haruo, Takao,Seishin, Suzuki,Ryusuke, Shirato,Hiroki, Ito,M. Yoichi
J Radiat Res, 58, 3, 363, 371, OXFORD UNIV PRESS, Oct. 2016, [Peer-reviewed]
English, Scientific journal, To investigate the amount that radiation-induced secondary cancer would be reduced by using proton beam therapy (PBT) in place of intensity-modulated X-ray therapy (IMXT) in pediatric patients, we analyzed lifetime attributable risk (LAR) as an in silico surrogate marker of the secondary cancer after these treatments. From 242 pediatric patients with cancers who were treated with PBT, 26 patients were selected by random sampling after stratification into four categories: (i) brain, head and neck, (ii) thoracic, (iii) abdominal, and (iv) whole craniospinal (WCNS) irradiation. IMXT was replanned using the same computed tomography and region of interest. Using the dose-volume histograms (DVHs) of PBT and IMXT, the LARs of Schneider et al were calculated for the same patient. All the published dose-response models were tested for the organs at risk. Calculation of the LARs of PBT and IMXT based on the DVHs was feasible for all patients. The means ± standard deviations of the cumulative LAR difference between PBT and IMXT for the four categories were (i) 1.02 ± 0.52% (n = 7, P = 0.0021), (ii) 23.3 ± 17.2% (n = 8, P = 0.0065), (iii) 16.6 ± 19.9% (n = 8, P = 0.0497)

胸腹部2点測定式呼吸モニタリング装置と呼吸同期システムを組み合わせた呼吸同期照射の精度検証
新谷 直也, 門前 一, 田村 昌也, 浅井 義行, 霜村 康平, 松本 賢治, 奥村 雅彦, 西村 恭昌
医学物理, 35, 4, 282, 291, (公社)日本医学物理学会, Feb. 2016
Japanese

Accuracy Verification of Respiratory-gated Radiotherapy that Combines the Respiration-Monitoring Device and Respiratory-gated System.
Shintani N, Monzen H, Tamura M, Asai Y, Shimomura K, Matsumoto K, Okumura M, Nishimura Y
Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics, 35, 4, 282, 291, Japan Society of Medical Physics, 2016, [Peer-reviewed]
Japanese, The purpose of this study is to evaluate the mechanical accuracy of a respiratory-gated radiation system that combines the Linear Indicator-equipped Abches respiration-monitoring device and the Varian Real-time Position Management system (LI-RPM system). This combined configuration, implemented for the first time in Japan, was compared with the stand-alone Varian RPM system (RPM system). The delay times, dose profiles, and output waveforms of the LI-RPM and RPM systems were evaluated using a self-produced dynamic phantom. The delay times for the LI-RPM and RPM systems were both 0.1 s for 4 s and 8 s test periods. The corresponding output waveform correlation factors (R²) for the 4 s and 8 s test periods were 0.9981 and 0.9975, respectively. No difference was observed in the dose profiles of the two systems. Thus, the present results indicate that the proposed LI-RPM combined respiratory-gated radiation system has similar properties to the RPM system. However, it offers several advantages in terms of its versatility, including its alignment assistance capabilities for non-coplanar treatments.

[Neutron Dosimetry System Using CR-39 for High-energy X-ray Radiation Therapy].
Yabuta K, Monzen H, Tamura M, Tsuruta T, Itou T, Nohtomi A, Nishimura Y
Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics, 34, 3, 139, 148, 2014, [Peer-reviewed]

A prospective clinical trial of tumor hypoxia imaging with 18f-fluoromisonidazole positron emission tomography and computed tomography (f-miso pet/ct) before and during radiation therapy
Izumi Tachibana, Yasumasa Nishimura, Toru Shibata, Shuichi Kanamori, Kiyoshi Nakamatsu, Ryuta Koike, Tatsuyuki Nishikawa, Kazuki Ishikawa, Masaya Tamura, Makoto Hosono
Journal of Radiation Research, 54, 6, 1078, 1084, Nov. 2013, [Peer-reviewed]
English

Dosimetric properties and clinical application of an a-Si EPID for dynamic IMRT quality assurance
Kenji Matsumoto, Masahiko Okumura, Yoshiyuki Asai, Kouhei Shimomura, Masaya Tamura, Yasumasa Nishimura
Radiological Physics and Technology, 6, 1, 210, 218, Jan. 2013, [Peer-reviewed]
English, Scientific journal

Volume and dosimetric changes and initial clinical experience of a two-step adaptive intensity modulated radiation therapy (IMRT) scheme for head and neck cancer
Tamaki Nishi, Yasumasa Nishimura, Toru Shibata, Masaya Tamura, Naohiro Nishigaito, Masahiko Okumura
Radiotherapy and Oncology, 106, 1, 85, 89, Jan. 2013, [Peer-reviewed]
English, Scientific journal

A method of neutron energy evaluation by using an imaging plate and cone-like acryl converters with a geometrical modulation concept
Nohtomi, A, Sugiura, N, Itoh, T, Wakabayashi, G, Sakae, T, Terunuma, T, Yabuta, K, Tamura, M, Fujibuchi, T, Takata, T, Kume, K
NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT, 633, 1, 36, 45, ELSEVIER SCIENCE BV, Mar. 2011, [Peer-reviewed]
English, Scientific journal

The effect of gantry and collimator angles on leaf limited velocity and position in dynamic multileaf collimator intensity-modulated radiation therapy.
Okumura M, Obata Y, Shimomura K, Tamura M, Nishimura Y
Physics in medicine and biology, 55, 11, 3101, 3113, Jun. 2010, [Peer-reviewed]

A Two-step Intensity-modulated Radiation Therapy Method for Nasopharyngeal Cancer: The Kinki University Experience
Yasumasa Nishimura, Toru Shibata, Kiyoshi Nakamatsu, Shuichi Kanamori, Ryuta Koike, Mitsuru Okubo, Tatsuyuki Nishikawa, Izumi Tachibana, Masaya Tamura, Masahiko Okumura
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 40, 2, 130, 138, Feb. 2010, [Peer-reviewed]
English, Scientific journal

A Preliminaly investigation on the satellite building of MLF; Beamline shielding analysis　　　　　　　　　　　　　　　
Oikawa, Kenichi, Maekawa, Fujio, Tamura, Masaya, Harada, Masahide, Kato, Takashi, Ikeda, Yujiro, Niita, Koji
LA-UR-06-3904, Vol.2, 139, 145, Jun. 2006
English, A preliminary investigation on a satellite building for a long-beamline instrument of MLF is now in progress. In order to estimate the total cost of the building, we started the shielding analysis of the beamline using MCNPX and PHITS, where the latest beamline design and the neutron spectrum have been adopted.

Design of "NeutrOn Beam-line for Observation \& Research Use (NOBORU)" for JSNS of J-PARC　　　　　　　　　　　　　　　
Maekawa, Fujio, Oikawa, Kenichi, Tamura, Masaya, Harada, Masahide, Ikeda, Yujiro, Watanabe, Noboru
LA-UR-06-3904, Vol.1, 129, 138, Jun. 2006
English, Total 23 neutron beam-lines will be installed for JSNS in the J-PARC project. One of them is assigned for the Materials and Life Science Facility (MLF), and the MLF will construct a neutron beam-line to demonstrate and monitor neutronic performance of JSNS. The neutron beam-line was accordingly named as "Neutron Beam-line for Obserbation and Research Use (NOBORU)". Major parts of the NOBORU, i.e., beam ducts, shield, a beam stop, slits, a cabin for measurement, a pillar crane, a sample table, etc., have been ordered in March 2004, and installation will be completed in 2007. A T0 chopper, a frame-overlap chopper, detector systems, samples, etc. will be ordered later on. The sample position is at 14 m from the decoupled moderator. Approximate sample room dimensions are 3 $\times$ 2.5 m in area and 3 m in height. A shield structure was determined by shielding calculations in which detailed 3-D structure was considered. The design of NOBORU will be presented in the session.

A New method for neutron-beam-line shielding calculation　　　　　　　　　　　　　　　
Maekawa, Fujio, Tamura, Masaya, Kawai, Masayoshi, Furusaka, Michihiro, Watanabe, Noboru
Proceedings of ICANS-XVI, Volume 3, 1247, 1255, Jul. 2003
English, A method for neutron-beam-line shielding calculation with a Monte Carlo code was newly developed. In the first step, components inside the biological shield such as a target-moderator-reflector-assembly and a neutron-beam-line were modeled, and a neutron current distribution along a duct of the neutron-beam-line was calculated. In the second step, decreases of neutron current along the beam-line were regarded as source terms for the beam-line shield, and required beam-line shield thickness was calculated. The most remarkable feature of this method was accurate treatment of the neutron source term distribution along the beam-line in the second step calculation. The followings were evaluated for JSNS by applying this method: (1) neutron-beam-line shield thickness with an empirical formula for estimating shield thickness conveniently, (2) beam stop sizes, (3) dose rates at a sample position when a shutter was closed, and (4) activation level of a To-chopper blade. These results gave conditions for determining the layout of 23 neutron-beam-lines in the experimental hall.

3-D shielding calculation method for 1-MW JSNS　　　　　　　　　　　　　　　
Maekawa, Fujio, Tamura, Masaya
Proceedings of ICANS-XVI, Volume 3, 1051, 1058, Jul. 2003
English, A three-dimensional (3-D) shielding calculation model for MCNPX was produced for shielding design of 1-MW JSNS. The model included simplified target-moderator-reflector assembly, helium-vessel and neutron beam extraction pipes, shutters, shield blocks, gaps and void spaces between these components, and so on, and could treat streaming effects precisely. The particle splitting and kill method with cell importance parameters was adopted as a variance reduction method. The cell importance parameters for such a large target station of about 15 m in diameter and 12 m in hight in which neutron fluxes attenuated more than 12 orders of magnitude could be determined appropriately by automated iteration calculations. This calculation procedure enabled detailed 3-D shielding design calculations for the whole target station in a short time, i.e., within 2 days, and contributed for progress of shielding designs of JSNS.

Effect of lead converter on superheated drop detector response to high-energy neutrons
T Sawamura, JH Kaneko, M Abe, M Tamura, Murai, I, A Homma, F Fujita, S Tsuda
NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT, 505, 1-2, 29, 32, Jun. 2003
English, Scientific journal

Measurement of mass attenuation coefficients around the K absorption edge by parametric X-rays
M Tamura, T Akimoto, Y Aoki, J Ikeda, K Sato, F Fujita, A Homma, T Sawamura, M Narita
NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT, 484, 1-3, 642, 649, May 2002
English, Scientific journal

Generation and use of parametric X-rays with an electron linear accelerator
T Akimoto, M Tamura, J Ikeda, Y Aoki, F Fujita, K Sato, A Honma, T Sawamura, M Narita, K Imai
NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT, 459, 1-2, 78, 86, Feb. 2001
English, Scientific journal

Normal Tissue Complication Probability for Hematologic and Gastrointestinal Toxicity in Postoperative Whole Pelvic Radiotherapy for Gynecologic Malignancies using Intensity Modulated Proton Therapy with Robust Optimization
T. Yoshimura, R. Yamada, R. Kinoshita, H. Tamura, T. Matsuura, S. Takao, M. Tamura, S. Tanaka, N. Nagae, K. Kobashi, H. Aoyama, S. Shimizu, International Journal of Radiation Oncology*Biology*Physics, 108, 3, e494, e494, Nov. 2020, [Peer-reviewed]
Elsevier BV, Summary international conference

局所進行食道癌に対してspot scanning法による根治的化学陽子線療法を施行した一例　　　　　　　　　　　　　　　
宮崎 智彦, 打浪 雄介, 田口 大志, 加藤 徳雄, 清水 伸一, 白土 博樹, 中積 宏之, 中野 真太郎, 坂本 直哉, 高尾 聖心, 田村 昌也, 松浦 妙子, 日本医学放射線学会秋季臨床大会抄録集, 55回, S520, S520, Sep. 2019
(公社)日本医学放射線学会, Japanese

Intensity-Modulated Proton Therapy with Dose Painting based on Hypoxia Imaging for Nasopharyngeal Cancer
K. Yasuda, S. Takao, Y. Matsuo, T. Yoshimura, M. Tamura, H. Minatogawa, Y. Dekura, T. Matsuura, R. Onimaru, T. Shiga, S. Shimizu, K. Umegaki, H. Shirato, International Journal of Radiation Oncology*Biology*Physics, 102, 3, e378, e378, Nov. 2018, [Peer-reviewed]
Elsevier BV, Summary international conference

An Evaluation Method of Lifetime Attributable Risk for Comparing Between Proton Beam Therapy and Intensity Modulated X-Ray Therapy for Pediatric Cancer Patients by Averaging Four Dose-Response Models for Carcinoma Induction
M. Tamura, Y. Ito, H. Sakurai, M. Mizumoto, S. Kamizawa, S. Murayama, H. Yamashita, S. Takao, R. Suzuki, H. Shirato, MEDICAL PHYSICS, 43, 6, 3508, 3508, Jun. 2016
English, Summary international conference

高リスク前立腺癌に対する放射線治療　　　　　　　　　　　　　　　
中松 清志, 横川 正樹, 田村 昌也, 西村 恭昌, Japanese Journal of Radiology, 34, Suppl., 44, 44, Feb. 2016
(公社)日本医学放射線学会, Japanese

当院における前立腺癌125I密封小線源永久挿入療法　　　　　　　　　　　　　　　
横川 正樹, 中松 清志, 西川 龍之, 田村 昌也, 金森 修一, 小池 竜太, 立花 和泉, 石川 一樹, 松浦 知弘, 建部 仁志, 西村 恭昌, Japanese Journal of Radiology, 33, Suppl., 71, 71, Feb. 2015
(公社)日本医学放射線学会, Japanese

A Neutron Dosimetry System Using CR-39 for High-energy X-ray Radiation Therapy
YABUTA KAZUTOSHI, MONZEN HAJIME, TAMURA MASAYA, TSURUTA TAKAO, ITO TETSUO, NOTOMI AKIHIRO, NISHIMURA YASUMASA, 医学物理, 34, 3, 139, 148, 31 Jan. 2015
Japanese

Brachytherapy for patients with intermediate‐risk prostate cancer at a single institution
YOKOKAWA Masaki, NAKAMATSU Kiyoshi, NISHIKAWA Tatsuyuki, TAMURA Masaya, MATSUURA Tomohiro, TACHIBANA Izumi, TATEBE Hitoshi, ISHIKAWA Kazuki, KANAMORI Shuichi, NISHIMURA Yasumasa, 日本医学放射線学会総会抄録集, 73rd, S389, 28 Feb. 2014
English

頭頸部腫瘍に対するPET/CT simulationを用いた放射線治療成績
MATSUURA TOMOHIRO, TACHIBANA IZUMI, KANAMORI SHUICHI, NAKAMATSU KIYOSHI, YOKOGAWA MASAKI, KOIKE RYUTA, NISHIKAWA TATSUYUKI, ISHIKAWA KAZUKI, TAMURA MASAYA, OKUBO MITSURU, NISHIMURA YASUMASA, Jpn J Radiol, 32, Supplement, 36, 36, 25 Feb. 2014
(公社)日本医学放射線学会, Japanese

高リスク前立腺癌に対するIMRT
NAKAMATSU KIYOSHI, TAMURA MASAYA, NISHIMURA YASUMASA, Jpn J Radiol, 32, Supplement, 43, 25 Feb. 2014
Japanese

A Neutron Dosimetry System Using CR-39 for High-energy X-ray Radiation Therapy
Yabuta Kazutoshi, Monzen Hajime, Tamura Masaya, Tsuruta Takao, Itou Tetsuo, Nohtomi Akihiro, Nishimura Yasumasa, Japanese Journal of Medical Physics, 34, 3, 139, 148, 2014
Neutrons are produced during radiation treatment by megavolt X-ray energies. However, it is difficult to measure neutron dose especially just during the irradiation. Therefore, we have developed a system for measuring neutrons with the solid state track detector CR-39, which is free from the influence of the X-ray beams. The energy spectrum of the neutrons was estimated by a Monte Carlo simulation method, and the estimated neutron dose was corrected by the contribution ratio of each energy.Pit formation rates of CR-39 ranged from 2.3×10-3 to 8.2×10-3 for each detector studied. According to the estimated neutron energy spectrum, the energy values for calibration were 144 keV and 515keV, and the contribution ratios were approximately 40:60 for 10 MV photons and 20:70 for photons over 15 MV. Neutron doses measured in the center of a high-energy X-ray field were 0.045 mSv/Gy for a 10 MV linear accelerator and 0.85 mSv/Gy for a 20 MV linear accelerator.We successfully developed the new neutron dose measurement system using the solid track detector, CR-39. This on-time neutron measurement system allows users to measure neutron doses produced in the radiation treatment room more easily., Japan Society of Medical Physics, Japanese

ハイリスク前立腺癌に対するIMRTの治療成績
NAKAMATSU KIYOSHI, NISHIMURA YASUMASA, YOKOGAWA MASAKI, TAMURA MASAYA, SHIBATA TOORU, 日本医学放射線学会総会抄録集, 72nd, S230, 28 Feb. 2013
Japanese

高リスク前立腺癌症例に対する125Iシード線源治療
YOKOGAWA MASAKI, NAKAMATSU KIYOSHI, NISHIKAWA TATSUYUKI, TAMURA MASAYA, UEMURA HIROTSUGU, MINAMI TAKAFUMI, NISHIMURA YASUMASA, 日本医学放射線学会総会抄録集, 72回, S397, S397, Feb. 2013
(公社)日本医学放射線学会, Japanese

頭頸部腫瘍に対する強度変調放射線治療の確立と標準化のための臨床研究 IMRTの品質管理・品質保証に関する研究
TAMURA MASAYA, 頭頸部腫瘍に対する強度変調放射線治療の確立と標準化のための臨床研究 平成24年度 総括・分担研究報告書, 12, 13, 2013
Japanese

頭頸部腫瘍に対する強度変調放射線治療の確立と標準化のための臨床研究 IMRTの品質管理・品質保証に関する研究
TAMURA MASAYA, 頭頸部腫瘍に対する強度変調放射線治療の確立と標準化のための臨床研究 平成23年度 総括・分担研究報告書, 9, 10, 2012
Japanese

異なる放射線治療計画装置によるDynamic‐IMRT治療計画の比較
TAMURA MASAYA, SHIBATA TOORU, NISHIMURA YASUMASA, SHINTANI NAOYA, SHIMOMURA KOHEI, NISHI TAMAKI, OKUMURA MASAHIKO, Jpn J Radiol, 29, Supplement 1, 49, 25 Jan. 2011
Japanese

肛門管癌に対する根治的放射線治療の検討
TACHIBANA IZUMI, SHIBATA TOORU, KANAMORI SHUICHI, NAKAMATSU KIYOSHI, TAMURA MASAYA, KOIKE RYUTA, NISHIKAWA TATSUYUKI, OKUBO MITSURU, NISHIMURA YASUMASA, Jpn J Radiol, 29, Supplement 1, 42, 25 Jan. 2011
Japanese

高精度治療技術による低リスク高線量放射線治療に関する臨床研究 非小細胞肺癌に対するIMRTに関する研究
NISHIMURA YASUMASA, NAKAMATSU KIYOSHI, TAMURA MASAYA, 高精度治療技術による低リスク高線量放射線治療に関する臨床研究 平成22年度 総括研究報告書, 64, 66, 2011
Japanese

限局型前立腺癌に対するI125シード線源治療後の尿路合併症
NAKAMATSU KIYOSHI, OKUBO MITSURU, TAMURA MASAYA, NISHIMURA YASUMASA, 日本医学放射線学会総会抄録集, 69th, S305, 28 Feb. 2010
Japanese

前立腺癌IMRTの線量増加の治療成績と晩期有害事象の検討
SHIBATA TOORU, NAKAMATSU KIYOSHI, TAMURA MASAYA, NISHIKAWA TATSUYUKI, KOIKE RYUTA, TACHIBANA IZUMI, KANAMORI SHUICHI, NISHIMURA YASUMASA, 日本医学放射線学会総会抄録集, 69th, S302, 28 Feb. 2010
Japanese

ガントリならびにコリメータ角度におけるDMLCの速度と位置の精度評価に関する検討
OKUMURA MASAHIKO, SHIMOMURA KOHEI, TAMURA MASAYA, MATSUMOTO KENJI, ASAI YOSHIYUKI, OBATA YASUNORI, 日本放射線技術学会総会学術大会予稿集, 66th, 221, 222, 26 Feb. 2010
Japanese

高精度治療技術による低リスク高線量放射線治療に関する臨床研究 非小細胞肺癌に対するIMRTに関する研究
NISHIMURA YASUMASA, TAMURA MASAYA, 高精度治療技術による低リスク高線量放射線治療に関する臨床研究 平成21年度 総括研究報告書, 54, 55, 2010
Japanese

肛門管癌に対する根治的放射線治療の臨床成績
TACHIBANA IZUMI, SHIBATA TOORU, KANAMORI SHUICHI, NAKAMATSU KIYOSHI, TAMURA MASAYA, KOIKE RYUTA, NISHIKAWA TATSUYUKI, NISHIMURA YASUMASA, 日本放射線腫よう学会誌, 21, Supplement 1, 126, 19 Aug. 2009
Japanese

Dynamic‐MLC動作精度の定量的評価法の開発
SHIMOMURA KOHEI, MATSUMOTO KENJI, OKUMURA MASAHIKO, TAMURA MASAYA, NISHIMURA YASUMASA, 日本放射線腫よう学会誌, 21, Supplement 1, 173, 19 Aug. 2009
Japanese

前立腺癌に対するI125シード線源治療後の晩期直腸合併症
NAKAMATSU KIYOSHI, OKUBO MITSURU, TAMURA MASAYA, NISHIMURA YASUMASA, 日本放射線腫よう学会誌, 21, Supplement 1, 155, 19 Aug. 2009
Japanese

Pinnacle3を用いたDynamic‐IMRT治療計画の検討
TAMURA MASAYA, SHINTANI NAOYA, SHIMOMURA KOHEI, NISHI TAMAKI, NAGAHATA TOMOMASA, YABUTA KAZUTOSHI, 医学物理 Supplement, 29, 2, 260, 261, Apr. 2009
Japanese

Dynamic MLC IMRTにおける線量分布にbeam hold offが及ぼす影響について
OKUMURA MASAHIKO, SHIMOMURA KOHEI, TAMURA MASAYA, NISHI TAMAKI, OBATA YASUNORI, 日本放射線技術学会総会学術大会予稿集, 65th, 239, 27 Feb. 2009
Japanese

IMRT‐QA解析アプリケーションを用いたDMLC動作特性の検証
TAMURA MASAYA, NISHI TAMAKI, OKUMURA MASAHIKO, MATSUMOTO KENJI, SHIMOMURA KOHEI, SHINTANI NAOYA, SAKAGUCHI KAYUKO, ASAI YOSHIYUKI, SHIBATA TOORU, NISHIMURA YASUMASA, 日本放射線腫よう学会誌, 20, Supplement 1, 148, 22 Sep. 2008
Japanese

Dynamic MLCファイルの解析によるIMRT照射条件の改善について
NISHI TAMAKI, TAMURA MASAYA, OKUMURA MASAHIKO, ASAI YOSHIYUKI, SAKAGUCHI KAYUKO, SHINTANI NAOYA, MATSUMOTO KENJI, SHIMOMURA KOHEI, NISHIMURA YASUMASA, 日本放射線腫よう学会誌, 20, Supplement 1, 149, 22 Sep. 2008
Japanese

トモセラピーの現状と遠隔治療計画支援システム
SHIBAMOTO YUTA, SUGIE CHIKAO, OGINO HIROYUKI, ODA KYOTA, KATO TOKUSHI, TAMURA MASAYA, MATSUO MASAYUKI, MIMURA MIKIO, Radiat Med, 26, Suppl.I, 33, 33, 25 Apr. 2008
(公社)日本医学放射線学会, Japanese

Palliative radiotherapy for bone metastases with TomoTherapy
ODA KYOTA, TAMURA MASAYA, TAKADA NAOYUKI, KATO NORIFUMI, SHIBAMOTO YUTA, 臨床放射線, 52, 12, 1691, 1698, 10 Nov. 2007
金原出版, Japanese

TomoTherapy―新世代放射線治療機の導入と実際の運用―
ODA KEITA, TAMURA MASAYA, TAKADA NAOYUKI, KATO NORIFUMI, SHIBAMOTO YUTA, 日本癌治療学会誌, 42, 2, 751, 20 Sep. 2007
Japanese

緩和医療におけるTomoTherapyの意義―骨転移に対する治療から
ODA KYOTA, TAMURA MASAYA, TAKADA TADAYUKI, KATO NORIFUMI, SHIBAMOTO YUTA, 日本医学放射線学会学術集会抄録集, 66th, S329, 28 Feb. 2007
Japanese

TomoTherapyによる高精度放射線治療の経験
ODA KEITA, TAMURA MASAYA, TAKADA NAOYUKI, KATO NORIFUMI, SHIBAMOTO YUTA, 臨床放射線, 51, 12, 1776, 1782, 10 Nov. 2006
金原出版, Japanese

良性脳腫瘍に対するTomoTherapy
ODA KYOTA, TAMURA MASAYA, TAKADA NOBUYUKI, KATO NORIFUMI, KAMATA HAJIME, SHIBAMOTO YUTA, 日本放射線腫よう学会誌, 18, Supplement 1, 192, 25 Oct. 2006
Japanese

TomoTherapyによる高精度放射線治療
ODA KYOTA, KATO TOKUSHI, TAMURA MASAYA, GOTO SHIN'ICHI, KAMATA HAJIME, SHIRATO HIROKI, SHIBAMOTO YUTA, 日本医学放射線学会学術集会抄録集, 65th, S214, 25 Feb. 2006
Japanese

Helical tomotherapyのためのコミッショニングドジメトリ
GOTO SHIN'ICHI, ODA KYOTA, TAMURA MASAYA, KATO TOKUSHI, NAGAO KICHISUKE, IDE AYUMI, SHIBAMOTO YUTA, 日本放射線腫よう学会誌, 17, Supplement 1, 137, 25 Oct. 2005
Japanese

Pinnacleを用いた強度変調放射線治療のInverse PlanningとTomoTherapyへの一考察
TAMURA MASAYA, SHIRATO HIROKI, AOYAMA EIJI, FUJINO KENJI, FUJITA KATSUHISA, ONIMARU RIKIYA, KATO TOKUSHI, ODA KYOTA, IDE WATARU, SHIBAMOTO YUTA, 日本放射線腫よう学会誌, 17, Supplement 1, 102, 102, 25 Oct. 2005
(公社)日本放射線腫瘍学会, Japanese

画像誘導放射線治療(原標題は英語)
SHIRATO HIROKI, SUZUKI KEISHIRO, NISHIOKA TAKESHI, TAMURA MASAYA, ONIMARU RIKIYA, AOYAMA HIDEFUMI, 日本医学放射線学会秋季臨床大会抄録集, 41st, S462, 05 Sep. 2005
Japanese

JSNS分光器中性子ビームライン遮蔽概念設計
KAWAI MASAYOSHI, NIITA KOJI, MAEKAWA FUJIO, OIKAWA KEN'ICHI, KAJIMOTO RYOICHI, KAMIYAMA TAKASHI, SUZUYA KENTARO, TAMURA MASAYA, NAKAJIMA KENJI, HARADA MASAHIDE, 日本原子力学会秋の大会予稿集(CD-ROM), 2005, C24, 12 Aug. 2005
Japanese

Shielding Design for Target Trolley for a Spallation Neutron Source in the J-PARC Project
TAMURA MASAYA, MAEKAWA FUJIO, HARADA MASAHIDE, HAGA KATSUHIRO, KONNO CHIKARA, 日本原子力研究所JAERI-Tech, 63P, Mar. 2005
Japanese

J‐PARC核破砕中性子源施設における水銀ターゲット台車の遮蔽検討
TAMURA MASAYA, MAEKAWA FUJIO, HAGA KATSUHIRO, KONNO CHIKARA, 日本原子力学会春の年会要旨集, 42nd, 0144, 11 Mar. 2004
Japanese

Shielding Study on Mercury Target Trolley for J-PARC Spallation Neutron Source Facility
TAMURA MASAYA, MAEKAWA FUJIO, HAGA KATSUHIRO, KONNO CHIKARA, Proceedings of Annual / Fall Meetings of Atomic Energy Society of Japan, 2004, 0, 56, 56, 2004
以前の検討以来、J-PARC核破砕中性子源施設における水銀ターゲット台車設計の詳細化及び建屋設計の変更が行われ、また以前はターゲット台車と台車周りのライナーとのギャップによるストリーミングを考慮していなかった。そこで今回、モデルを最新設計に合わせて更新し、さらにストリーミングを考慮して再評価を行った。計算を2つの段階に分けた。第一段階として、ターゲット台車を水銀配管を含めて3次元モデル化し、台車周辺の線量分布をNMTC/JAMを用いて求めた。第二段階として、先の計算で求めた台車後端部の中性子束を線源として、一次元球体系モデルを用い、1.5mのコンクリート壁の背後にあるマニピュレータ室（目標線量25μSv/h以下）、さらに1.5mのコンクリート壁の背後にある一般区域（同0.5μSv/h以下）における線量をMCNPXにより求めた。鉄遮蔽の増加、さらにギャップによるストリーミングを抑制することで、台車後端部において目標線量を下回る遮蔽構造を考案した。一次元球体系モデルによる計算から、マニピュレータ室及び一般区域で線量限度以下にできることを確認し、ターゲット台車の遮蔽構造を決定した。, Atomic Energy Society of Japan

J‐PARC/MLF実験施設の長尺建家に関する予備検討~遮蔽検討~
OIKAWA KEN'ICHI, TAMURA MASAYA, HARADA MASAHIDE, MAEKAWA FUJIO, KATO TAKASHI, IKEDA YUJIRO, 日本中性子科学会年会講演概要集, 4th, 105, 2004
Japanese

J‐PARC核破砕中性子源におけるビームライン遮蔽厚簡易評価式
TAMURA MASAYA, MAEKAWA FUJIO, OIKAWA KEN'ICHI, HARADA MASAHIDE, KATO TAKASHI, IKEDA YUJIRO, 日本中性子科学会年会講演概要集, 4th, 101, 2004
Japanese

JSNSビームラインタスクグループ活動報告
OIKAWA KEN'ICHI, MAEKAWA FUJIO, TAKADA HIROSHI, SOYAMA KAZUHIKO, YOSHIDA KATSUHIKO, FURUSAKA MICHIHIRO, ARAI MASATOSHI, TAMURA MASAYA, IKEDA YUJIRO, 日本中性子科学会年会講演概要集, 3rd, 49, 10 Dec. 2003
Japanese

核破砕中性子源施設の3次元遮蔽設計 計算手法
MAEKAWA FUJIO, TAMURA MASAYA, IKEDA YUJIRO, 日本原子力学会春の年会要旨集, 41st, 149, 05 Mar. 2003
Japanese

核破砕中性子源施設の3次元遮蔽設計 計算結果
TAMURA MASAYA, MAEKAWA FUJIO, IKEDA YUJIRO, 日本原子力学会春の年会要旨集, 41st, 150, 05 Mar. 2003
Japanese

3-Dimensional Shielding Design for a Spallation Neutron Source Facility in the High-intensity Proton Accelerator Project
TAMURA MASAYA, MAEKAWA FUJIO, 日本原子力研究所JAERI-Tech, 60P, Mar. 2003
Japanese

パラメトリックX線放射の強度特性
YOSHIDA TSUYOSHI, AKIMOTO TADASHI, TAMURA MASAYA, FUJITA FUMIYUKI, MURAI IKUO, SATO KOICHI, SHIMAZU YOICHIRO, NARITA MASAKUNI, IMAI KAZUAKI, 応用物理学会学術講演会講演予稿集, 63rd, 1, 86, 24 Sep. 2002
Japanese

過熱液滴型中性子線量計の高エネルギー領域における応答
SAITO TSUKASA, SAWAMURA TERUKO, TAMURA MASAYA, YAMADA TAKUMA, ABE MASASHI, MURAI IKUO, HONMA AKIRA, FUJITA FUMIYUKI, TSUDA SHUICHI, 日本原子力学会秋の大会予稿集, 2001, 58, 10 Aug. 2001
Japanese

パラメトリックX線による標的結晶の特性測定
TAMURA MASAYA, AKIMOTO TADASHI, IKEDA JIRO, HARA YUKIHIRO, FUJITA FUMIYUKI, HONMA AKIRA, SAWAMURA TERUKO, NARITA MASAKUNI, IMAI KAZUAKI, 日本原子力学会秋の大会予稿集, 2001, 183, 10 Aug. 2001
Japanese

パラメトリックX線放射のスペクトル測定 (III)
TAMURA MASAYA, AKIMOTO TADASHI, IKEDA JIRO, FUJITA FUMIYUKI, HONMA AKIRA, SATO KOICHI, SAWAMURA TERUKO, NARITA MASAKUNI, 日本原子力学会秋の大会予稿集, 1999, 52, 10 Aug. 1999
Japanese

Study of the Parametric X-ray spectrum. (II).
TAMURA MASAYA, AKIMOTO TADASHI, FUJITA FUMIYUKI, HONMA AKIRA, SATO KOICHI, TANIDA HIROAKI, SAWAMURA TERUKO, NARITA MASAKUNI, 日本原子力学会秋の大会予稿集, 1998, 116, Sep. 1998
Japanese

Generation of parametric X-ray by electron beam accelerator, and its characteristics.
TAMURA MASAYA, AKIMOTO TADASHI, FUJITA FUMIYUKI, HONMA AKIRA, SATO KOICHI, TANIDA HIROAKI, SAWAMURA TERUKO, NARITA MASAKUNI, UTNL-R(東京大学大学院工学系研究科附属原子力工学研究施設), 361, 39, 40, Jan. 1998
Japanese